Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Adamgammadex vs Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Blockade at PTC 1–2
ChiCTR2200056471Phase 3Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adamgammadex in reversal of nondepolarizing neuromuscular blockade (2 arms), sponsored by Renji Hospital. Primary endpoint: Time to TOFr 0.9. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
adamgammadex
03
Conditions
reversal of nondepolarizing neuromuscular blockade
Beyond the preview
Go deeper on ChiCTR2200056471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056471.